Cytomel-T3 50mcg/tab 50 Tabletten by Beligas Pharmaceuticals

Usage

1. Establish your anabolic base first: begin your testosterone or AAS compound two to three weeks before the first T3 tablet to ensure stable anabolic plasma levels are in place as a catabolic buffer.
2. Start at 25 mcg/day by splitting the scored tablet cleanly; take the dose in the morning to align with the body's natural cortisol and thyroid rhythm and minimise sleep disruption from elevated metabolic rate.
3. Progress to 50 mcg/day after seven to fourteen days if no adverse cardiac or neurological symptoms are present — palpitations or excessive heat intolerance are signals to hold at the current dose rather than escalate.
4. Distribute the dose across two administrations (morning and midday) if using 75 mcg/day or above; this smooths plasma Liothyronine concentration peaks and reduces peak-dose cardiovascular load.
5. Track lean mass markers weekly — monitor morning fasted weight alongside a strength benchmark lift; if strength drops faster than scale weight, increase dietary protein above 2.2 g/kg and reassess AAS dose adequacy.
6. Taper T3 over the final five to seven days rather than stopping abruptly; abrupt cessation can produce rebound symptoms and slows HPT axis normalisation — maintain the AAS base throughout the taper until the scheduled cycle endpoint.

Warnings

Frequently asked questions

Why is running T3 without anabolic steroids so damaging to muscle tissue?

T3 at performance doses accelerates amino acid catabolism alongside fat oxidation, pushing nitrogen balance into negative territory. Without anabolic steroids to upregulate protein synthesis through androgen receptor pathways, the body draws on skeletal muscle as a fuel substrate. Clinical nitrogen excretion data confirm measurable lean tissue loss at supraphysiological T3 doses when no anabolic compound is present to counteract this catabolic drive.

What is the minimum effective AAS dose to protect muscle mass during a T3 cut?

A conservative anti-catabolic threshold is Testosterone Enanthate at 200–300 mg per week — sufficient to maintain positive nitrogen retention and androgen receptor activation without introducing excessive anabolic stimulus. Higher-dose AAS stacks offer greater protection but also greater risk; many experienced athletes view 250 mg/week of testosterone as the practical floor for lean tissue preservation when T3 exceeds 50 mcg per day.

How do you recognise that T3-driven catabolism is outpacing fat loss in a cycle?

Key indicators include disproportionate strength loss relative to scale weight reduction, flat or visually deflated muscle bellies despite maintained caloric intake, and increasing perceived fatigue under load. If strength drops faster than body weight — particularly across compound lifts — it is a reliable clinical signal that lean tissue is being sacrificed. DEXA imaging, where available, provides objective confirmation within two to three weeks of protocol onset.

Can Beligas Cytomel-T3 tablets be split for lower starting doses?

Yes. The 50 mcg tablets are scored, allowing a clean split to approximately 25 mcg — the dose most protocols use as a ramp-up starting point before progressing to 50 or 75 mcg daily. Splitting is practical for fine-tuning thyroid hormone exposure during the early weeks of a cycle, particularly when the anabolic base is still building to stable plasma concentrations.

How many tablets are in a pack and what does that mean for a standard T3 cycle?

Each pack contains 50 tablets at 50 mcg each. At a standard dose of 50 mcg per day, one pack covers a full 50-day run — sufficient for most six-to-eight-week cutting protocols with a small buffer. Users who split tablets at 25 mcg/day during the ramp-up phase can extend pack coverage further, making the 50-tablet blister a practical match for typical cycle lengths without mid-cycle restocking. (2) angle_used

Manufacturer

Quality release at Beligas Pharmaceuticals, for Cytomel-T3 specifically, is structured around the recognition that Liothyronine Sodium presents one of the narrowest therapeutic indices in the oral performance compound category — and that narrow therapeutic index demands chromatographic precision, not label approximation. The release workflow assigns each production lot a mandatory HPLC quantification step: the Liothyronine peak is isolated from tablet excipient matrix via High-Performance Liquid Chromatography, then measured against a certified pharmacopoeial reference standard to produce a lot-specific, numerically confirmed per-tablet content value. That figure — not the nominal label claim — is what appears on the batch release certificate. The practical significance for end users running dose-sensitive protocols is direct: when the daily dose split across two administrations is 50 mcg, a five-to-ten mcg variance per tablet translates into a compounding exposure error that becomes clinically meaningful by week two or three of a cycle. Beligas' HPLC-based release criterion eliminates that source of variance at the manufacturing stage, before any tablet reaches the end user. This is the quality control logic that underpins the HPLC-Verified designation carried by Cytomel-T3.